intramuscular paraldehyde

Phase 3Small molecule

KKamuzu University of Health Sciences

intramuscular paraldehyde is one of 5 small molecule programs targeting Convulsion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConvulsionActive, not recruiting

ConvulsionPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Convulsion

#DrugCompanyPhaseTrials

Vimpat

UCB

Approved

—2

Eraxis

VVicuron Pharmaceuticals

Approved

—3

intramuscular paraldehyde

KKamuzu University of Health Sciences

Phase 3

1 4

Keppra

UCB

Preclinical

1 5

Valium

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Convulsion1 trial

Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions

Completed·KKamuzu University of Health Sciences·Phase 3·NCT00116064·156 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intramuscular paraldehyde. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intramuscular paraldehyde compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intramuscular paraldehyde. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kamuzu University of Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKamuzu University of Health Sciences

intramuscular paraldehyde

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Convulsion1 trial

References

Drug Info

Quick Facts

Related News